Fixed Duration of Venetoclax-Rituximab for CLL May Prolong Survival

Share this content:
When used as a fixed-duration venetoclax-rituximab combination, 62% of patients achieved an undetectable minimal residual disease level in peripheral blood.
When used as a fixed-duration venetoclax-rituximab combination, 62% of patients achieved an undetectable minimal residual disease level in peripheral blood.

A longer follow-up of a phase 3 study confirmed that fixed-duration venetoclax-rituximab therapy delivers durable clinical responses and a survival advantage compared with bendamustine-rituximab therapy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Researchers report in the Journal of Clinical Oncology that venetoclax, which is a highly selective inhibitor of B-cell lymphoma, showed continued benefit compared with bendamustine, and predicted longer progression-free survival (PFS).1

Arnon Kater, MD, PhD, with Amsterdam Universitair Medische Centra, University of Amsterdam, the Netherlands, and colleagues examined treatment effect and minimal residual disease (MRD) kinetics now that all the patients in the phase 3 arm of the MURANO trial have stopped receiving this treatment.

Continue Reading Below

In the trial, patients were randomly assigned to receive either 2 years of venetoclax plus rituximab during the first 6 cycles or 6 cycles of bendamustine-rituximab. The researchers found that 90% of patients completed the venetoclax-rituximab phase (174 of 194) and 67% of patients completed 2 years of venetoclax (130 of 194). The PFS rates at a median follow-up of 36 months showed venetoclax-rituximab was superior to bendamustine-rituximab (hazard ratio [HR], 0.16; median not reached vs 17.0 months, respectively). The study showed that the 3-year PFS estimates were 71.4% for patients given venetoclax-rituximab and 15.2% for those in the bendamustine-rituximab arm.

The researchers also found that patients who received venetoclax-rituximab achieved a higher rate of peripheral blood undetectable MRD (uMRD) at the end of combination therapy (EOCT) than did patients who were administered bendamustine-rituximab (62% vs 13%, respectively), with superiority sustained through month 24. The study also revealed that uMRD status at EOCT was able to predict longer PFS.

Reference

  1. Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase 3 study [published online December 3, 2018]. J Clin Oncol. doi: 10.1200/JCO.18.01580

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs